Search - tctmd.com

Displaying 761 - 780 of 1231

Sort: Relevancy | Date

News Daily News

首个 NOAC 逆转剂 Idarucizumab 获批；不太可能耽误介入治疗

October 26, 2015

News Daily News

First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions

October 26, 2015

News Daily News

Aprobado el Idarucizumab, Primer Antídoto de NOAC; El Deseo es no Demorar las Intervenciones

October 26, 2015

My Takeaways From TCT 2015

News Opinion Editor's Corner TCT 2015

My Takeaways From TCT 2015

October 20, 2015

News Industry News

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

October 20, 2015

Is There a Role for Oral Anticoagulants After PCI?

Presentation TCT 2015

Is There a Role for Oral Anticoagulants After PCI?

Presenter: Eric R. Bates, Neal S. Kleiman, C. Michael Gibson

October 15, 2015

Vorapaxar: Lessons From the Randomized Trials in ACS and for Secondary Prevention

Presentation TCT 2015

Vorapaxar: Lessons From the Randomized Trials in ACS and for Secondary Prevention

Presenter: Eric R. Bates, Neal S. Kleiman, Ori Ben-Yehuda

October 15, 2015

Should You Bridge in Stented Patients Needing Surgery?

Presentation TCT 2015

Should You Bridge in Stented Patients Needing Surgery?

Presenter: Eric R. Bates, Neal S. Kleiman, David F. Kong

October 15, 2015

What Is the Optimal Anticoagulant for Transradial PCI?

Presentation TCT 2015

What Is the Optimal Anticoagulant for Transradial PCI?

Presenter: Olivier F. Bertrand, John A. Bittl

October 15, 2015

News Industry News

Similar Results With Bivalirudin Compared With Heparin Anticoagulation In TAVR Patients

October 15, 2015

News Conference News TCT 2015

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Yael L. Maxwell

October 15, 2015

Can We Drop Aspirin? Pharmacodynamic Insights on Adding an Oral Anticoagulant to Antiplatelet Therapy With and Without Aspirin

Presentation TCT 2015

Can We Drop Aspirin? Pharmacodynamic Insights on Adding an Oral Anticoagulant to Antiplatelet Therapy With and Without Aspirin

Presenter: Pascal Vranckx, Freek W.A. Verheugt

October 14, 2015

News Conference News TCT 2015

Discussion Highlights Merits, Limitations of Small Trials

Yael L. Maxwell

October 13, 2015

Procedural Anticoagulants in Sweden: Results From the SCAAR Registry and Rationale for VALIDATE-SWEDEHEART

Presentation TCT 2015

Procedural Anticoagulants in Sweden: Results From the SCAAR Registry and Rationale for VALIDATE-SWEDEHEART

Presenter: John A. Bittl, Robert A. Harrington, David Erlinge

October 12, 2015

I Dont Believe Bivalirudin Should Routinely Be Used as the First-line Anticoagulant in Primary PCI!

Presentation TCT 2015

I Dont Believe Bivalirudin Should Routinely Be Used as the First-line Anticoagulant in Primary PCI!

Presenter: Nick Curzen, Ajay J. Kirtane, David J. Cohen

October 12, 2015

News Conference News TCT 2015

LAA Closure Trials Illustrate Evolution of Devices, Trial Design

October 12, 2015

How Good Is LAA Closure Compared to Oral Anticoagulants? Results of Studies

Presentation TCT 2015

How Good Is LAA Closure Compared to Oral Anticoagulants? Results of Studies

Presenter: Russell A. Brandwein, Elizabeth M Perpetua

October 11, 2015

News Conference News TCT 2015

Use of LAA Occlusion in Low-Risk Patients Debated

October 11, 2015

News Conference News TCT 2015

Cath Lab Economics: Pursuit of a Light at the End of the Tunnel

October 11, 2015

News Daily News

Reduced Leaflet Motion in Bioprosthetic Aortic Valves Not Uncommon But Remedied by Anticoagulation

October 08, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.